TP53 and neoplasm: Therefore, we suggest that pre-treatment of tumor-bearing mice with p53 agonists may; 1) decrease desmoplasia and thereby improve tumor accessibility and efficacy of Gemcitabine, and 2) protect normal cells from the genotoxic effects of Gemcitabine.